
CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-1
CAS:<p>Cdc7-IN-1: selective ATP-competitive Cdc7 kinase inhibitor; IC50 0.6 nM at 1mM ATP; induces cancer cell death.</p>Formula:C21H16ClN3O4Color and Shape:SolidMolecular weight:409.82CDK9-IN-14
CAS:<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Formula:C21H23F2N3O4Color and Shape:SolidMolecular weight:419.42CLK1/2-IN-3
CAS:<p>CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.</p>Formula:C21H21N5O2Purity:99.04%Color and Shape:SolidMolecular weight:375.42THZ1-R
CAS:<p>THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.</p>Formula:C31H30ClN7O2Purity:98%Color and Shape:SolidMolecular weight:568.07CLK1-IN-1
CAS:<p>CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).</p>Formula:C24H16FN5OColor and Shape:SolidMolecular weight:409.42CDK12-IN-E9
CAS:<p>CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.</p>Formula:C24H30N6O2Color and Shape:SolidMolecular weight:434.53Cdc7-IN-17
CAS:<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Formula:C13H15N5OSColor and Shape:SolidMolecular weight:289.36AS2863619 free base
CAS:<p>AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.</p>Formula:C16H12N8OColor and Shape:SolidMolecular weight:332.32Cdc7-IN-4
CAS:<p>Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.</p>Formula:C22H24F3N5O4Purity:98%Color and Shape:SolidMolecular weight:479.45K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Formula:C15H13F2N7O2S2Purity:99.12%Color and Shape:SolidMolecular weight:425.44CDK8-IN-7
CAS:<p>CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.</p>Formula:C30H40N2Color and Shape:SolidMolecular weight:428.65Cdc7-IN-15
CAS:<p>Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].</p>Formula:C12H14N4OSColor and Shape:SolidMolecular weight:262.33CP681301
CAS:<p>CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.</p>Formula:C17H22N4OColor and Shape:SolidMolecular weight:298.38MDK6204
CAS:<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Formula:C20H20N6OPurity:98%Color and Shape:SolidMolecular weight:360.41BSJ-01-175
CAS:<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Formula:C30H33ClN6O2Color and Shape:SolidMolecular weight:545.08Indirubin-3'-monoxime-5-sulphonic acid
CAS:<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Formula:C16H11N3O5SPurity:98%Color and Shape:SolidMolecular weight:357.34CDK7-IN-13
CAS:<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Formula:C20H23F3N6OSPurity:99.22%Color and Shape:SolidMolecular weight:452.5P18IN003
CAS:<p>P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of</p>Formula:C17H16N2O3Purity:98.77%Color and Shape:SolidMolecular weight:296.32CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Formula:C30H26N6O3Color and Shape:SolidMolecular weight:518.57FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Formula:C25H28F2N8Color and Shape:SolidMolecular weight:478.54BS-181
CAS:<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Formula:C22H32N6Purity:98%Color and Shape:SolidMolecular weight:380.53CDK4/6-IN-12
CAS:<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Formula:C12H10N6Color and Shape:SolidMolecular weight:238.25CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Formula:C18H18ClN5OPurity:98.81%Color and Shape:SolidMolecular weight:355.82CCT068127
CAS:<p>CCT068127 is a potent CDK2 and CDK9 inhibitor.</p>Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.46(S)-CR8
CAS:<p>(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.</p>Formula:C24H29N7OColor and Shape:SolidMolecular weight:431.53CDK7-IN-8
CAS:<p>CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.</p>Formula:C25H38N8O3Color and Shape:SolidMolecular weight:498.62EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Formula:C24H21N3O4S2Color and Shape:SolidMolecular weight:479.57Aloisine A
CAS:<p>Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.</p>Formula:C16H17N3OPurity:98%Color and Shape:SolidMolecular weight:267.33TP1287
CAS:<p>TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.</p>Formula:C21H21ClNO8PColor and Shape:SolidMolecular weight:481.82Indirubin-5-sulfonate
CAS:<p>Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.</p>Formula:C16H10N2O5SPurity:98%Color and Shape:SolidMolecular weight:342.33Crozbaciclib fumarate
CAS:<p>Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.</p>Formula:C32H34F2N6O4Color and Shape:SolidMolecular weight:604.65CDK7-IN-12
CAS:<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Formula:C20H19F3N6Color and Shape:SolidMolecular weight:400.4CDK1-IN-1
CAS:<p>CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.</p>Formula:C27H23N5O3Color and Shape:SolidMolecular weight:465.5CDK4/6-IN-9
CAS:<p>CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.</p>Formula:C22H23FN8Color and Shape:SolidMolecular weight:418.47Cdc7-IN-13
CAS:<p>Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].</p>Formula:C18H20N4O2SColor and Shape:SolidMolecular weight:356.44Ulecaciclib
CAS:<p>Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).</p>Formula:C25H33FN8SColor and Shape:SolidMolecular weight:496.65FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Formula:C22H25N9OPurity:97.4%Color and Shape:SolidMolecular weight:431.49JTK-101
CAS:<p>JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.</p>Formula:C25H23N3O3Color and Shape:SolidMolecular weight:413.47(E/Z)-BIO-acetoxime
CAS:<p>(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.</p>Formula:C18H12BrN3O3Color and Shape:SolidMolecular weight:398.21(S)-LY3177833 hydrate
CAS:<p>(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.</p>Formula:C16H14FN5O2Color and Shape:SolidMolecular weight:327.31RP-106
CAS:<p>RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.</p>Formula:C17H19N3OPurity:98%Color and Shape:SolidMolecular weight:281.35PKC-9
CAS:<p>PKC-9 is a PKC-zeta inhibitor 9.</p>Formula:C25H25N7Color and Shape:SolidMolecular weight:423.51CDK4/6-IN-7
CAS:<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Formula:C18H18ClN5O3Color and Shape:SolidMolecular weight:387.82Cdc7-IN-3
CAS:<p>Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.</p>Formula:C20H22N4O5Purity:98%Color and Shape:SolidMolecular weight:398.41CDK7-IN-2
CAS:<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Formula:C26H39N7O3Color and Shape:SolidMolecular weight:497.63EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Formula:C23H21N3O3S2Color and Shape:SolidMolecular weight:451.56CDK5 inhibitor 20-223
CAS:<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Formula:C19H19N3OColor and Shape:SolidMolecular weight:305.37FN-1501-propionic acid
CAS:<p>FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.</p>Formula:C25H27N9O4Purity:98%Color and Shape:SolidMolecular weight:517.54EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Formula:C23H20N4O5S2Color and Shape:SolidMolecular weight:496.56CDK8-IN-10
CAS:<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Formula:C25H15ClF3N5O3Color and Shape:SolidMolecular weight:525.87
